Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warning Letter Roundup & Recap

This article was originally published in The Silver Sheet

Executive Summary

Zoll cited for QS and MDR violations; FDA instructs maker of drug-of-abuse kits to hire a consultant to audit the firm’s manufacturing and quality assurance systems; Ambco Electronics failed to fully investigate and document device failures. Eight quality-related warning letters were listed by FDA from Sept. 12 through Oct. 14.

You may also be interested in...



Court Revives Zoll Product Safety Suit Following Earlier Premption Ruling

The Eleventh Circuit Court of Appeals reversed a lower court's decision that US FDA regulations pre-empted a product liability suit against Zoll Medical. The suit was filed by the son of a woman who allegedly died after her Zoll LifeVest external defibrillator malfunctioned.

US FDA Commissioner Hahn’s Star Turn: Baptism By Fire Turns Perilous

Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?

Keeping Track: US FDA Okays BMS’ Zeposia In MS, Nixes Lilly/BI’s Empagliflozin For Type 1 Diabetes

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

MT036827

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel